- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 285/12 - 1,3,4-ThiadiazolesHydrogenated 1,3,4-thiadiazoles
Patent holdings for IPC class C07D 285/12
Total number of patents in this class: 184
10-year publication summary
|
16
|
17
|
10
|
5
|
4
|
6
|
7
|
1
|
8
|
2
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4812 |
6 |
| Oryzon Genomics S.A. | 102 |
5 |
| Reata Pharmaceuticals, Inc. | 117 |
5 |
| Receptos LLC | 61 |
5 |
| Array BioPharma Inc. | 458 |
4 |
| The Lubrizol Corporation | 1259 |
4 |
| Omeros Corporation | 304 |
4 |
| Merck Sharp & Dohme LLC | 3723 |
4 |
| Glaxo Group Limited | 4365 |
3 |
| The Arizona Board of Regents on Behalf of the University of Arizona | 2258 |
3 |
| KYORIN Pharmaceutical Co., Ltd. | 162 |
3 |
| Ohio State Innovation Foundation | 2314 |
3 |
| Piramal Enterprises Limited | 151 |
3 |
| PRAECIS Pharmaceuticals Incorporated | 9 |
3 |
| Proteostasis Therapeutics, Inc. | 69 |
3 |
| PTC Therapeutics, Inc. | 472 |
3 |
| Taisho Pharmaceutical Co., Ltd. | 858 |
3 |
| Toyama Chemical Co., Ltd. | 93 |
3 |
| BASF SE | 21129 |
2 |
| Amgen Inc. | 4353 |
2 |
| Other owners | 113 |